Show simple item record

dc.contributor.authorPenney, Jay
dc.contributor.authorRalvenius, William
dc.contributor.authorTsai, Li-Huei
dc.date.accessioned2020-07-27T19:48:34Z
dc.date.available2020-07-27T19:48:34Z
dc.date.issued2019-08
dc.date.submitted2019-04
dc.identifier.issn1359-4184
dc.identifier.issn1476-5578
dc.identifier.urihttps://hdl.handle.net/1721.1/126402
dc.description.abstractAlzheimer’s disease is a devastating neurodegenerative disorder with no cure. Countless promising therapeutics have shown efficacy in rodent Alzheimer’s disease models yet failed to benefit human patients. While hope remains that earlier intervention with existing therapeutics will improve outcomes, it is becoming increasingly clear that new approaches to understand and combat the pathophysiology of Alzheimer’s disease are needed. Human induced pluripotent stem cell (iPSC) technologies have changed the face of preclinical research and iPSC-derived cell types are being utilized to study an array of human conditions, including neurodegenerative disease. All major brain cell types can now be differentiated from iPSCs, while increasingly complex co-culture systems are being developed to facilitate neuroscience research. Many cellular functions perturbed in Alzheimer’s disease can be recapitulated using iPSC-derived cells in vitro, and co-culture platforms are beginning to yield insights into the complex interactions that occur between brain cell types during neurodegeneration. Further, iPSC-based systems and genome editing tools will be critical in understanding the roles of the numerous new genes and mutations found to modify Alzheimer’s disease risk in the past decade. While still in their relative infancy, these developing iPSC-based technologies hold considerable promise to push forward efforts to combat Alzheimer’s disease and other neurodegenerative disorders.en_US
dc.description.sponsorshipNIH (Grants RF1 AG054012, RF1 054321 and R37 NS051874)en_US
dc.language.isoen
dc.publisherSpringer Science and Business Media LLCen_US
dc.relation.isversionofhttp://dx.doi.org/10.1038/s41380-019-0468-3en_US
dc.rightsCreative Commons Attribution 4.0 International licenseen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.sourceNatureen_US
dc.titleModeling Alzheimer’s disease with iPSC-derived brain cellsen_US
dc.typeArticleen_US
dc.identifier.citationPenney, Jay et al. "Modeling Alzheimer’s disease with iPSC-derived brain cells." Molecular Psychiatry 25, 1 (August 2019): 148–167. © 2019 The Author(s)en_US
dc.contributor.departmentPicower Institute for Learning and Memoryen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Brain and Cognitive Sciencesen_US
dc.relation.journalMolecular Psychiatryen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2019-10-09T12:49:44Z
dspace.date.submission2019-10-09T12:49:46Z
mit.journal.volume25en_US
mit.journal.issue1en_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record